Selected article for: "current prevalence and general population"

Author: Naderi, Majid; Malek, Fatemeh; Miri Aliabad, Ghasem; Behnampoor, Mahammad; de Sanctis, Vincenzo; Karimi, Mehran
Title: Congenital Bleeding Disorders amid the COVID-19 pandemic: open questions and recommendations
  • Cord-id: vl1l4xzv
  • Document date: 2020_9_7
  • ID: vl1l4xzv
    Snippet: This article reviews the current knowledges of congenital bleeding disorders (CBD) amid the COVID-19 pandemic. It appears that CBD is not associated with higher risk of getting COVID-19 and so the prevalence of COVID-19 among them seems not higher compared to the general population. In absence of specific therapeutic recommendations, it is essential to make a correct assessment of the risk of haemorrhage/thrombosis. Based on expert opinion, strategies for outpatient management include adherence
    Document: This article reviews the current knowledges of congenital bleeding disorders (CBD) amid the COVID-19 pandemic. It appears that CBD is not associated with higher risk of getting COVID-19 and so the prevalence of COVID-19 among them seems not higher compared to the general population. In absence of specific therapeutic recommendations, it is essential to make a correct assessment of the risk of haemorrhage/thrombosis. Based on expert opinion, strategies for outpatient management include adherence to prescribed regimens, telemedicine, and communication about COVID-19 in patients with CBD. More data should be also collected to better characterize the impact of COVID-19 on patients with CBD. The current findings encourage further studies to determine the prevalence of SARS-CoV2 infection in CBD patients to understand more fully the burden of this novel pathogen and to develop adequate preventive measures against this infection. (www.actabiomedica.it)

    Search related documents:
    Co phrase search for related documents
    • accurate diagnosis and low molecular: 1, 2
    • active bleeding and low molecular: 1, 2, 3
    • active bleeding and low molecular weight heparin: 1, 2, 3
    • active treatment and low molecular: 1, 2
    • active treatment and low molecular weight heparin: 1, 2
    • low molecular and lung microvascular: 1, 2, 3
    • low molecular and lung microvascular thrombosis: 1, 2, 3
    • low molecular weight heparin and lung microvascular: 1, 2
    • low molecular weight heparin and lung microvascular thrombosis: 1, 2